STEMLINE THERAPEUTICS INC
DelistedCIK 1264587fmd_0SCHMX2M6X307PMM19H037R1QDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2004 to Mar 31, 2020, 41 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 1 | 1 | 1 | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | 5 |
| Research and development | – | 2 | 3 | 16 | 21 | 29 | 28 | 50 | 48 | 51 |
| Selling, general and administrative | – | – | – | – | – | – | – | 19 | 39 | 67 |
| Total operating expenses | – | 3 | 6 | 24 | 29 | 38 | 40 | 69 | 87 | – |
| Operating income | – | (3) | (6) | (24) | (29) | (38) | (39) | (69) | (86) | (79) |
| Interest expense | – | 0 | 0 | 1 | – | – | – | – | 0 | 0 |
| Interest and investment income | – | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Other non-operating income (expense) | – | – | – | – | – | 0 | 0 | (0) | (0) | (0) |
| Income before taxes | – | – | – | – | (29) | (37) | (38) | (68) | (85) | (77) |
| Income tax expense | – | – | – | – | – | 0 | (0) | 0 | 0 | (0) |
| Net income from continuing operations | (2) | (3) | (6) | (24) | (29) | (37) | (38) | (68) | (85) | (77) |
| Net income | – | – | – | – | – | (37) | (38) | (68) | (85) | (77) |
| Net income to common shareholders | – | (3) | (6) | (24) | (29) | (37) | (38) | – | – | – |